Metabolic Profiling as a Tool for Understanding Mechanisms of Toxicity

被引:149
作者
Clarke, Christopher J. [1 ]
Haselden, John N. [1 ]
机构
[1] Novartis Pharma AG, Preclin Safety, CH-4002 Basel, Switzerland
关键词
Metabonomics; preclinical safety assessment/risk management; pathobiology; biochemistry; biomarkers;
D O I
10.1177/0192623307310947
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Metabolic profiling (metabolomics/metabonomics) is the measurement in biological systems of the complement of low-molecular-weight metabolites and their intermediates that reflects the dynamic response to genetic modification and physiological, pathophysiological, and/or developmental stimuli. The measurement and interpretation of the endogenous metabolite profile from a biological sample (typically urine, serum, or biological tissue extract) have provided many opportunities to investigate the changes induced by external stimuli (e. g., drug treatment) or enhance our knowledge of inherent biological variation within subpopulations. This article will focus on the basic principles of metabolic profiling and how the tools (nuclear magnetic resonance [NMR], liquid chromatography-mass spectrometry [LC-MS]) can be applied in toxicology and pathology. Metabolic profiling can complement conventional methodologies and other "omics" technologies in investigating preclinical drug development issues. Case studies will illustrate the value of metabolic profiling in improving our understanding of phospholipidosis and peroxisome proliferation. A key message will be that metabolic profiling offers huge potential to highlight biomarkers and mechanisms in support of toxicology and pathology investigations in preclinical drug development.
引用
收藏
页码:140 / 147
页数:8
相关论文
共 12 条
[1]   Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation [J].
Delaney, J ;
Hodson, MP ;
Thakkar, H ;
Connor, SC ;
Sweatman, BC ;
Kenny, SP ;
McGill, PJ ;
Holder, JC ;
Hutton, KA ;
Haselden, JN ;
Waterfield, CJ .
ARCHIVES OF TOXICOLOGY, 2005, 79 (04) :208-223
[2]   Phenylacetylglycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model [J].
Delaney, J ;
Neville, WA ;
Swain, A ;
Miles, A ;
Leonard, MS ;
Waterfield, CJ .
BIOMARKERS, 2004, 9 (03) :271-290
[3]   Metabolomics - the way forward [J].
Goodacre, Royston .
METABOLOMICS, 2005, 1 (01) :1-2
[4]   A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects [J].
Lenz, EM ;
Bright, J ;
Wilson, ID ;
Morgan, SR ;
Nash, AFP .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 33 (05) :1103-1115
[5]   Contemporary issues in toxicology - The role of metabonomics in toxicology and its evaluation by the COMET project [J].
Lindon, JC ;
Nicholson, JK ;
Holmes, E ;
Antti, H ;
Bollard, ME ;
Keun, H ;
Beckonert, O ;
Ebbels, TM ;
Reilly, MD ;
Robertson, D ;
Stevens, GJ ;
Luke, P ;
Breau, AP ;
Cantor, GH ;
Bible, RH ;
Niederhauser, U ;
Senn, H ;
Schlotterbeck, G ;
Sidelmann, UG ;
Laursen, SM ;
Tymiak, A ;
Car, BD ;
Lehman-McKeeman, L ;
Colet, JM ;
Loukaci, A ;
Thomas, C .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 187 (03) :137-146
[6]   Metabonomics in pharmaceutical R & D [J].
Lindon, John C. ;
Holmes, Elaine ;
Nicholson, Jeremy K. .
FEBS JOURNAL, 2007, 274 (05) :1140-1151
[7]   Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity [J].
Mortishire-Smith, RJ ;
Skiles, GL ;
Lawrence, JW ;
Spence, S ;
Nicholls, AW ;
Johnson, BA ;
Nicholson, JK .
CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (02) :165-173
[8]  
Nicholls AW, 2000, BIOMARKERS, V5, P410, DOI 10.1080/135475000750052420
[9]   'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data [J].
Nicholson, JK ;
Lindon, JC ;
Holmes, E .
XENOBIOTICA, 1999, 29 (11) :1181-1189
[10]   Potential urinary and plasma biomarkersof peroxisome proliferation in the rat:: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography [J].
Ringeissen, S ;
Connor, SC ;
Brown, HR ;
Sweatman, BC ;
Hodson, MP ;
Kenny, SP ;
Haworth, RI ;
McGill, P ;
Price, MA ;
Aylott, MC ;
Nunez, DJ ;
Haselden, JN ;
Waterfield, CJ .
BIOMARKERS, 2003, 8 (3-4) :240-271